Study of Total Body Irradiation and Fludarabine Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation in Combination With Cyclosporine and Mycophenolate Mofetil in Patients With Inherited Disorders

You may be eligible if

• PROTOCOL ENTRY CRITERIA:
• -Disease Characteristics--
• Inherited disorders treatable with allogeneic peripheral blood or bone marrow transplantation At high risk for regimen related toxicity with a conventional transplant
• No severe CNS involvement of disease, defined by IQ score less than 70
• HLA matched donor Sibling donors must be a confirmed match at HLA-A, B, and DRB1 Other related and non-related donors must be matched at HLA-A, B, C, DRB1, and DQB1 A donor homozygous for one allele only at HLA-A, B, C, DRB1, or DQB1 allowed (1 antigen mismatch for graft-versus-host disease, 0 antigen mismatch for graft-rejection)
• -Prior/Concurrent Therapy--
• No concurrent growth factors with mycophenolate mofetil
• -Patient Characteristics--
• Age: Under 55
• Performance status: Not specified
• Life expectancy: At least 100 days
• Hematopoietic: Not specified
• Hepatic: No evidence of synthetic dysfunction No severe cirrhosis
• Renal: Not specified
• Cardiovascular: LVEF at least 30% No poorly controlled hypertension on multiple antihypertensives
• Other: No organ dysfunction that would preclude survival Not pregnant or nursing Fertile patients must use effective contraception during and for 12 months following study